BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), developer of the M-001 universal influenza vaccine candidate, reported today it will present this week at the World Vaccine & Immunotherapy Congress West Coast 2018 in San Diego.
Dr. Ron Babecoff, BiondVax’s Founder and CEO, will participate in a panel discussion and provide an overview of the Company’s achievements and plans, including the ongoing pivotal, clinical efficacy, Phase 3 trial.
Details of Dr. Babecoff’s presentations:
(1) Panel: How will we integrate knowledge gained from the UIVI and other research into the development of a Universal Influenza Vaccine?
Date: Wednesday, November 28, 2018
Time: 12:35pm
(2) Getting Closer to the Market: BiondVax’s Universal Flu Vaccine Pivotal Phase 3 Trial
Date: Wednesday, November 28, 2018
Time: 3:50pm
Those interested in meeting with Dr. Babecoff are invited to contact Joshua Phillipson at j.phillipson@biondvax.com.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.